Wu Ziliang, Wu Zelin, Zou Yawei, Guan Jingming, Wu Shangzhi, Chen Dehui
Department of Pediatrics, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, P.R. China.
Mol Clin Oncol. 2022 Oct 6;17(5):156. doi: 10.3892/mco.2022.2589. eCollection 2022 Nov.
Despite improvement in the long-term survival rate following pediatric acute myeloid leukemia (AML), the rate remains low, even with optimal treatment. The present study reports the long-term outcome of a small patient group treated with a single drug, high-dose chemotherapy (HDCT) with cytarabine, including consolidation and maintenance therapy. RT-PCR was conducted to assess 43 fusion genes, and after treatment, all cases have been followed up for 20 years (June 2002-December 2020). With an 80% 5-year survival rate, the results of this study highlight the possibility that pediatric AML can be reasonably effectively treated with relatively simple chemotherapy when necessary. HDCT is clinically safe, effective and relatively inexpensive. We propose that in the context of limited resources, HDCT should be considered as an alternative therapy for pediatric AML.
尽管小儿急性髓系白血病（AML）的长期生存率有所提高，但即便采用最佳治疗方案，该比率仍然较低。本研究报告了一小群接受单一药物大剂量化疗（HDCT）联合阿糖胞苷治疗的患者的长期预后，包括巩固治疗和维持治疗。进行逆转录聚合酶链反应（RT-PCR）以评估43种融合基因，治疗后，所有病例均已随访20年（2002年6月至2020年12月）。本研究结果显示5年生存率为80%，突出了小儿AML在必要时可通过相对简单的化疗得到合理有效治疗的可能性。大剂量化疗在临床上安全、有效且相对便宜。我们建议，在资源有限的情况下，大剂量化疗应被视为小儿AML的替代治疗方法。
